Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,532.00    8.00 (0.52%)
Bid:
1,530.00
Ask:
1,533.00
Spread: 3.00 (0.196%)
Market Cap: £3.22b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

LTIP Awards

30 Apr 2008 15:22

Hikma Pharmaceuticals Plc30 April 2008 Hikma Pharmaceuticals PLC - LTIP Awards LONDON, 30 April 2008: Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)announces that the Remuneration Committee has made the following nil-cost awardsunder the Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan (the "LTIP")to Directors and Persons Discharging Managerial Responsibility ("PDMRs") of theCompany. Awards under the LTIP were made on 29 April 2008 at a price of £4.64 perordinary share as follows:- Name of Director/PDMR Number of LTIP SharesSaid Darwazah 90,000Mazen Darwazah 54,000Bassam Kanaan 54,000Taghreed Al-Shunnar 54,000Majda Labadi 54,000Nabil Rizk 54,000 The shares subject to the LTIP awards will only be released to the participantsin three years time, subject to their continued employment and the satisfactionof the comparative Total Shareholder Return ("TSR") performance target.Participants will only receive the full benefit of their share incentives if TSRperformance against the Comparator Group is at least at the upper quartile. - ENDS -Enquiries: Hikma Pharmaceuticals PLCHenry Knowles +44 20 7399 2760Company Secretary Susan Ringdal +44 20 7399 2760Investor Relations Director About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed pharmaceutical products. Hikma's operationsare conducted through three businesses: "Branded", "Injectables" and"Generics". Hikma's operations are based principally in the Middle East andNorth Africa ("MENA") region, where it is a market leader and sells across 17countries, the United States and Europe. In 2007, the Group achieved revenuesof $449 million (2006 $317 million) and profit attributable to shareholders was$63 million (2006 $55 million). For news and other information, please visitwww.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
16th May 20133:32 pmRNSResult of AGM
16th May 20137:00 amRNSInterim Management Statement
10th May 20133:05 pmRNSDirector/PDMR Shareholding
2nd May 20133:16 pmRNSDirector/PDMR Shareholding
23rd Apr 20133:32 pmRNSDirector/PDMR Shareholding
18th Apr 201310:29 amRNSDirector/PDMR Shareholding
17th Apr 20137:00 amRNSHikma update on global Injectables business
10th Apr 20132:35 pmRNSAnnual Financial Report
5th Apr 201311:03 amRNSAnnual Information Update
5th Apr 201311:00 amRNSBlocklisting Interim Review
5th Apr 201310:53 amRNSTotal Voting Rights
25th Mar 20132:42 pmRNSDirector/PDMR Shareholding
13th Mar 20137:00 amRNSPreliminary Results
1st Mar 201310:24 amRNSResponse to unsolicited enquiries
4th Feb 201310:29 amRNSHikma signs agreement with EffRx
21st Jan 201310:17 amRNSAdditional Listing
9th Jan 20137:00 amRNSAcquisition
3rd Jan 20133:55 pmRNSTotal Voting Rights
3rd Jan 20133:49 pmRNSNon Regulatory Announcement
27th Dec 20123:31 pmRNSHolding(s) in Company
13th Dec 20127:00 amRNSProduct Launch
27th Nov 20121:45 pmRNSBuilding Public Trust Awards - Highly Commended
12th Nov 20129:48 amRNSTotal Voting Rights
2nd Nov 20127:00 amRNSInterim Management Statement
1st Nov 201210:02 amRNSHolding(s) in Company
22nd Oct 201210:13 amRNSHikma & GP Pharm signs license & supply agreement
11th Oct 20121:00 pmRNSInjectables Analyst and Investor Day USA
10th Oct 201210:27 amRNSBlocklisting Interim Review
10th Oct 201210:06 amRNSTotal Voting Rights
4th Oct 20129:29 amRNSDividend Declaration
16th Aug 20127:00 amRNSHalf Yearly Report
8th Aug 201210:03 amRNSHolding(s) in Company
6th Jul 201212:24 pmRNSTotal Voting Rights
3rd Jul 20125:36 pmRNSHolding(s) in Company
29th Jun 201212:22 pmRNSDirector/PDMR Shareholding
25th Jun 201211:20 amRNSDirector/PDMR Shareholding
21st Jun 20123:04 pmRNSDirector/PDMR Shareholding
6th Jun 201211:34 amRNSTotal Voting Rights
18th May 201210:46 amRNSDirector/PDMR Shareholding
17th May 20123:27 pmRNSResult of AGM
17th May 20127:00 amRNSInterim Management Statement
1st May 20123:50 pmRNSHolding(s) in Company
20th Apr 201212:50 pmRNSHolding(s) in Company
16th Apr 20129:57 amRNSAnnual Information Update
13th Apr 201211:39 amRNSAnnual Financial Report & AGM Notice
4th Apr 20124:15 pmRNSCompany Secretary Change
2nd Apr 20125:21 pmRNSTotal Voting Rights
2nd Apr 20125:14 pmRNSBlocklisting Interim Review
28th Mar 201211:12 amRNSDirector/PDMR Shareholding
19th Mar 20124:52 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.